Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $4.78

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has received an average recommendation of "Hold" from the eight brokerages that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $4.78.

Several brokerages have commented on IRWD. Leerink Partners lowered their price target on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a report on Monday, April 14th. Craig Hallum lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Jefferies Financial Group reiterated a "hold" rating and issued a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Wells Fargo & Company restated an "equal weight" rating and set a $1.00 price target (down from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Finally, Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Ironwood Pharmaceuticals Trading Down 1.3%

NASDAQ IRWD traded down $0.01 during trading on Friday, hitting $0.60. 1,737,311 shares of the company traded hands, compared to its average volume of 2,573,785. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $7.11. The business has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $2.22. The company has a market capitalization of $97.43 million, a P/E ratio of -20.07 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company had revenue of $41.14 million for the quarter, compared to analyst estimates of $67.02 million. Equities research analysts predict that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $36,000. McAdam LLC bought a new position in Ironwood Pharmaceuticals during the first quarter valued at about $40,000. Journey Strategic Wealth LLC acquired a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $45,000. Simplicity Wealth LLC bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth approximately $45,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $47,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.